Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases

Description

It is hypothesize that patients with clinically diagnosed neurodegenerative diseases will have significantly different receptor occupancy of 5HT2A receptors compared to a healthy age/sex-matched control group. This will be tested by measuring 5HT2A receptor density using the PET radioligand (R)-\[18F\]MH.MZ in both populations.

Conditions

Neurodegenerative Diseases, Parkinson Disease, Parkinson Disease Psychosis

Talk to us

Study Overview

On this page

Study Details

Study overview

It is hypothesize that patients with clinically diagnosed neurodegenerative diseases will have significantly different receptor occupancy of 5HT2A receptors compared to a healthy age/sex-matched control group. This will be tested by measuring 5HT2A receptor density using the PET radioligand (R)-\[18F\]MH.MZ in both populations.

Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases

Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases

Condition
Neurodegenerative Diseases
Intervention / Treatment

-

Contacts and Locations

Nashville

Vanderbilt University Medical Center, Nashville, Tennessee, United States, 37212

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patient arm - clinical diagnosis of Parkinson disease, diffuse Lewy body disease, multiple systems atrophy, Huntington's Disease, Frontotemporal Dementia, and other variants
  • * Healthy arm - age and gender matched to patient arm
  • * Psychosis (presence of hallucinations or delusions) starting after the diagnosis of Parkinson's disease, occurring at least weekly for 4 weeks, severe enough to warrant treatment.
  • * Study partner available for study visits
  • * Prior stroke or other uncontrolled serious neurological or medical illness
  • * Contra-indication or inability to tolerate MRI scan
  • * Use of serotonergic medications in the last 6 weeks
  • * Incapable of providing independent consent.
  • * Pregnant or breastfeeding women
  • * psychosis due to a metabolic, toxic, or primary psychiatric disease
  • * Deemed unable to complete neurocognitive testing
  • * For PD Participants: current or prior use of pimavanserin
  • * Use of antipsychotics in the last 2 weeks

Ages Eligible for Study

50 Years to 85 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Vanderbilt University Medical Center,

Daniel Claassen, MD, PRINCIPAL_INVESTIGATOR, Vanderbilt University Medical Center

Ciaran Considine, PhD, PRINCIPAL_INVESTIGATOR, Vanderbilt University Medical Center

Richard Darby, MD, PRINCIPAL_INVESTIGATOR, Vanderbilt University Medical Center

Study Record Dates

2025-08